Loading...
Market
Which continent outside Africa will first approve Lenacapavir for PrEP by end of 2025?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia • 25%
South America • 25%
Regulatory agency announcements and approval records
Story
Lenacapavir Reduces HIV Infection Risk to Nearly 0% in Phase 3 Trial, Injectable Every Six Months
Dec 8, 2024, 03:45 PM
Lenacapavir, a novel pre-exposure prophylaxis (PrEP), has shown promising results in reducing the risk of HIV infection to nearly 0% in a phase 3 trial involving adolescent girls and young women in South Africa and Uganda. Unlike traditional vaccines, lenacapavir is an antiretroviral drug that inhibits HIV replication rather than training the immune system to recognize the virus. It is administered just under the skin every six months. Additionally, another injectable PrEP, cabotegravir, is available, requiring an injection every two months. Both options provide new avenues for HIV prevention, highlighting the evolving landscape of antiretroviral therapies.
View original story
Similar markets
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
USA • 25%
European Union • 25%
Africa • 25%
Other • 25%
United States • 25%
South Africa • 25%
India • 25%
Other • 25%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
South Africa • 25%
Kenya • 25%
Nigeria • 25%
Other • 25%
United States • 25%
European Union • 25%
South Africa • 25%
Other • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%